- QIAGEN N.V. (NYSE:QGEN) will collaborate with Inovio Pharmaceuticals (NASDAQ:INO) to develop a liquid biopsy-based companion diagnostic test aimed at screening patients who would benefit from the latter's VGX-3100, a DNA-based immunotherapy for the potential treatment of cervical dysplasia (precancerous condition) caused by HPV.
- Financial terms are not disclosed.
- INO is up 1% after hours.